Squarepoint
GYRE icon

Squarepoint’s Gyre Therapeutics GYRE Stock Holding History

Squarepoint’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3,404
Closed -$105K – 3305
2021
Q3 		$105K Sell
3,404
-2,871
-46% -$94.5K ﹤0.01% 2654
2021
Q2 		$204K Sell
6,275
-3,031
-33% -$104K ﹤0.01% 2816
2021
Q1 		$352K Buy
+9,306
New +$425K ﹤0.01% 2281
2020
Q4 		– Sell
-3,861
Closed -$125K – 3046
2020
Q3 		$125K Sell
3,861
-955
-20% -$37.4K ﹤0.01% 2234
2020
Q2 		$212K Buy
4,816
+1,988
+70% +$93.3K ﹤0.01% 1798
2020
Q1 		$93K Buy
+2,828
New +$130K ﹤0.01% 1653
2019
Q3 		– Sell
-3,296
Closed -$182K – 2467
2019
Q2 		$182K Buy
3,296
+1,309
+66% +$81.8K ﹤0.01% 2124
2019
Q1 		$121K Buy
+1,987
New +$128K ﹤0.01% 2017
2018
Q4 		– Sell
-2,973
Closed -$240K – 2063
2018
Q3 		$240K Sell
2,973
-1,915
-39% -$152K ﹤0.01% 1663
2018
Q2 		$428K Buy
+4,888
New +$857K 0.01% 1240

Other funds holding GYRE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Squarepoint's GYRE Position: Q4 2021 in Review

Squarepoint sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 3,404 shares — an estimated $105K sold.

Squarepoint first reported a position in GYRE in Q2 2018 and held it in 10 quarters. The position peaked at $428K in Q2 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • Squarepoint reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Squarepoint sold 3,404 Gyre Therapeutics shares in Q4 2021, an estimated $105K.
  • Squarepoint first reported a position in Gyre Therapeutics in Q2 2018 and held it in 10 quarters.
  • Squarepoint's Gyre Therapeutics position peaked at $428K in Q2 2018.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Squarepoint's 13F filing for Q4 2021, filed 14 Feb 2022.